구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lymphokine-activated killer cells (lymphokine-activated killer cells) Lisata Therapeutics, Inc.·Colorectal Cancer 22 trials |
|---|---|
Overview Program | lymphokine-activated killer cells |
Overview Company | Lisata Therapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Colorectal Cancer |
Overview Indication | Brain and Central Nervous System Tumors |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | [The use of roncoleukin for LAK therapy in ovarian cancer].. Roncoleukin--recombinant IL-2--was studied with a view to application for LAK therapy. Lymph of ductus thoracicus from ovarian cancer patients receiving adjuvant autolymphochemotherapy was used as source of lymphocytes. Immunobiologic activity of lymphocytes was assayed after 30-minutes incubation with roncoleukin and 24- or 48-hours cul… |
Clinical Safety signal | [The use of roncoleukin for LAK therapy in ovarian cancer].. Roncoleukin--recombinant IL-2--was studied with a view to application for LAK therapy. Lymph of ductus thoracicus from ovarian cancer patients receiving adjuvant autolymphochemotherapy was used as source of lymphocytes. Immunobiologic activity of lymphocytes was assayed after 30-minutes incubation with roncoleukin and 24- or 48-hours cul… |
Clinical Selected reported efficacy | ORR 42% |
Clinical Reported ORR | 42% |
Clinical Result source | ClinicalTrials.gov NCT01857934 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01857934 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | lymphokine-activated killer cells (lymphokine-activated killer cells) Lisata Therapeutics, Inc.·Colorectal Cancer 22 trials |
|---|---|
Overview Program | lymphokine-activated killer cells |
Overview Company | Lisata Therapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Colorectal Cancer |
Overview Indication | Brain and Central Nervous System Tumors |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | [The use of roncoleukin for LAK therapy in ovarian cancer].. Roncoleukin--recombinant IL-2--was studied with a view to application for LAK therapy. Lymph of ductus thoracicus from ovarian cancer patients receiving adjuvant autolymphochemotherapy was used as source of lymphocytes. Immunobiologic activity of lymphocytes was assayed after 30-minutes incubation with roncoleukin and 24- or 48-hours cul… |
Clinical Safety signal | [The use of roncoleukin for LAK therapy in ovarian cancer].. Roncoleukin--recombinant IL-2--was studied with a view to application for LAK therapy. Lymph of ductus thoracicus from ovarian cancer patients receiving adjuvant autolymphochemotherapy was used as source of lymphocytes. Immunobiologic activity of lymphocytes was assayed after 30-minutes incubation with roncoleukin and 24- or 48-hours cul… |
Clinical Selected reported efficacy | ORR 42% |
Clinical Reported ORR | 42% |
Clinical Result source | ClinicalTrials.gov NCT01857934 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01857934 |
추천 비교
추천 비교